- Baricitinib demonstrated significant hair regrowth in adolescents with severe alopecia areata in a phase III clinical trial.
- 42.4% of adolescent patients achieved 80% or more scalp hair coverage after 36 weeks of treatment with baricitinib.
- The drug also showed efficacy in regrowing eyebrows and eyelashes.
- The safety profile observed in adolescent patients was consistent with prior clinical trials.
- Baricitinib was previously approved by the FDA in 2022 for adult patients with severe alopecia areata.
Baricitinib Effective for Teen Alopecia
Conexiant
March 10, 2025
